Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement following the announced FDA approval of Biogen's new Alzheimer's treatment Aducanumab.
Daniel Alkon, M.D., President and Chief Scientific Officer, stated, "We applaud the significant commitment that Biogen has made towards developing a new treatment option for Alzheimer's Disease (AD). Their dedication and persistence to finding a therapy deserves acknowledgement and gratitude. Synaptogenix shares Biogen's commitment to treat AD, although the focus of Synaptogenix resources remains toward a restorative approach, actual restoration of function and disease reversal, versus that of only a slowing of the disease's rate of clinical decline. The Synaptogenix lead compound Bryostatin, now in an extended clinical trial, is believed to work on regeneration of brain wiring (synaptic networks), in addition to a reduction of amyloid that is targeted by the Biogen compound. We believe that innovative, potentially restorative, drug targets will add to the potential therapeutic benefits that FDA-approved medications must eventually offer to the millions of AD patients in the U.S. and abroad."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.